Latest & greatest articles for Imiquimod

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Imiquimod or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Imiquimod and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Imiquimod

1. Imiquimod (Zyclara) - actinic keratosis

Imiquimod (Zyclara) - actinic keratosis 1 Published 11 November 2019 1 SMC2211 imiquimod 3.75% cream (Zyclara®) Meda Pharmaceuticals 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission imiquimod (Zyclara ® ) is accepted for restricted use within NHSScotland. Indication (...) or balding scalp achieved complete clearance when treated with imiquimod 3.75% cream compared with vehicle. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. 1 Dosing Information Up to two sachets of imiquimod 3.75

2019 Scottish Medicines Consortium

2. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) Full Text available with Trip Pro

Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN) To compare the recurrence rates after complete response to topical treatment with either cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3.A prospective, open, randomised multicentre trial.32 general hospitals located in Wales and England.180 patients were randomised consecutively between 21 October 2009 and 11 January (...) 2013, 89 to cidofoovir (of whom 41 completely responded to treatment) and 91 to imiquimod (of whom 42 completely responded to treatment).After 24 weeks of treatment, complete responders were followed up at 6-monthly intervals for 24 months. At each visit, the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 was assessed and any new lesions were biopsied for histology.Time to histologically confirmed disease recurrence (any grade of VIN).The median length of follow up was 18.4 months

2018 EvidenceUpdates

3. Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness

Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Imiquimod for the Treatment of Genital Warts: A Review of Clinical Effectiveness and Cost-Effectiveness Published on: September 25, 2017 Project (...) Number: RC0930-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of genital warts? What is the cost-effectiveness of imiquimod for the treatment of genital warts? Key Message Evidence from systematic reviews with low quality included studies suggests that overall for patients with anogenital warts (AGW) compared to placebo, treatment with imiquimod (IMQ) is associated

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness

Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness Published on: September 15, 2017 Project Number: RC0929-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of imiquimod for the treatment of actinic keratosis? What is the cost-effectiveness of imiquimod for the treatment of actinic keratosis? Key Message The three included systematic reviews showed that in patients with actinic keratosis (AK), treatment with imiquimod (IMQ) appeared to be better than placebo with respect to complete clearance.Few primary studies were available

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Use of topical imiquimod in the treatment of VIN: a case report and review of the literature Full Text available with Trip Pro

Use of topical imiquimod in the treatment of VIN: a case report and review of the literature Vulvar intraepithelial neoplasia (VIN) is a premalignant disease of the vulvar squamous epithelium. Standard treatment for VIN lesions is surgical excision. Alternative therapeutic options for conservative treatment have been sought by patients to prevent disfigurement and to preserve sexual function. We present such a patient in whom topical imiquimod was used with a successful outcome. Imiquimod

2016 International journal of women's dermatology

6. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RTVIN): a multicentre, open-label, randomised, phase 2 trial Full Text available with Trip Pro

Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RTVIN): a multicentre, open-label, randomised, phase 2 trial Vulval intraepithelial neoplasia is a skin disorder affecting the vulva that, if left untreated, can become cancerous. Currently, the standard treatment for patients with vulval intraepithelial neoplasia is surgery, but this approach does not guarantee cure and can be disfiguring, causing physical and psychological problems (...) , particularly in women of reproductive age. We aimed to assess the activity, safety, and feasibility of two topical treatments--cidofovir and imiquimod--as an alternative to surgery in female patients with vulval intraepithelial neoplasia.We recruited female patients (age 16 years or older) from 32 centres to an open-label, randomised, phase 2 trial. Eligibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 and at least one lesion that could be measured accurately. We randomly

2014 EvidenceUpdates Controlled trial quality: predicted high

7. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial (Abstract)

Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial Superficial basal-cell carcinoma is most commonly treated with topical non-surgical treatments, such as photodynamic therapy or topical creams. Photodynamic therapy is considered the preferable treatment, although this has not been previously tested in a randomised control trial. We assessed the effectiveness (...) of photodynamic therapy compared with imiquimod or fluorouracil in patients with superficial basal-cell carcinoma.In this single blind, non-inferiority, randomised controlled multicentre trial, we enrolled patients with a histologically proven superficial basal-cell carcinoma at seven hospitals in the Netherlands. Patients were randomly assigned to receive treatment with methylaminolevulinate photodynamic therapy (MAL-PDT; two sessions with an interval of 1 week), imiquimod cream (once daily, five times

2013 EvidenceUpdates Controlled trial quality: predicted high

8. Imiquimod for the Treatment of External Genital Warts in Adults: Clinical and Cost-effectiveness

Imiquimod for the Treatment of External Genital Warts in Adults: Clinical and Cost-effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Imiquimod for the Treatment

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Zyclara - imiquimod

Zyclara - imiquimod 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union 3 August 2012 EMA/525140/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Zyclara imiquimod Procedure No. EMEA/H/C/002387 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Zyclara (...) . Imiquimod is an immune response modifier. Saturable binding studies suggest that a membrane receptor for imiquimod exists on responding immune cells. Imiquimod has no direct antiviral activity. In animal models imiquimod is effective against viral infections and acts as an antitumour agent principally by induction of alpha interferon and other cytokines. The induction of alpha interferon and other cytokines following imiquimod cream application to genital wart tissue has also been demonstrated

2012 European Medicines Agency - EPARs

10. Zyclara (imiquimod) Cream

Zyclara (imiquimod) Cream Drug Approval Package: Zyclara (imiquimod) NDA #022483 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Zyclara (imiquimod) Cream, 3.75% Company: Graceway Pharmaceuticals, LLC Application No.: 022483 Approval Date: 3/25/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2010 FDA - Drug Approval Package

11. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia

More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia Mahto M, Nathan M, O'Mahony C CRD summary This review suggested that 5% imiquimod cream was reasonably well tolerated and may be an alternative treatment for vulvar, penile and anal intraepithelial (...) neoplasias; there was no evidence regarding comparisons with traditional treatments. The review may not be reliable due to the risk of missing data, limited analyses and reliance on poorer study designs. Authors' objectives To evaluate the effectiveness of 5% imiquimod cream for the treatment of vulvar, penile and anal intraepithelial neoplasias (VIN, PIN and AIN). Searching MEDLINE, EMBASE and The Cochrane Library were searched for English-language studies published between 1997 and May 2009. Search

2010 DARE.

12. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model

Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate (...) of imiquimod versus photodynamic therapy (PDT) for the treatment of solar or actinic keratosis of the face and scalp, in patients with four to nine lesions, who were unsuitable for cryosurgery, topical diclofenac, and topical fluorouracil. The author concluded that PDT was unlikely to be cost-effective compared with imiquimod and a head-to-head trial was needed. The methods were robust and transparently presented. The author’s conclusions appear to be valid. Type of economic evaluation Cost-utility

2010 NHS Economic Evaluation Database.

13. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review

Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

14. Imiquimod cream for the treatment of adult patients with actinic keratosis

Imiquimod cream for the treatment of adult patients with actinic keratosis Imiquimod cream for the treatment of adult patients with actinic keratosis | Therapeutics Initiative Independent Healthcare Evidence > > Imiquimod cream for the treatment of adult patients with actinic keratosis Introduction: This is an update to the February 2005 Therapeutics Initiative review of Imiquimod 5% cream (Aldara™) for the treatment actinic keratosis. Drug Imiquimod is an immune response modifier indicated (...) examination and not often confirmed by histology. Current standards of treatment: Cryosurgery and curettage are used for small areas with few lesions. Other treatment options include chemical peels, dermabrasion, laser therapy, excision and photodynamic therapy as well as retinoid therapy and intra lesional interferon. (Hadley G et al 2006) Research question In randomized controlled trials does imiquimod 5% cream provide a therapeutic advantage compared to no treatment, placebo (vehicle) or other standard

2009 Therapeutics Letter

15. Imiquimod cream for actinic keratosis

Imiquimod cream for actinic keratosis Imiquimod cream for actinic keratosis | Therapeutics Initiative Independent Healthcare Evidence > > Imiquimod cream for actinic keratosis This is the summary of an update of the February 2005 Therapeutics Initiative systematic review of imiquimod 5% cream (Aldara) for the treatment of actinic keratosis. Drug Imiquimod is an immune response modifier indicated for the treatment of clinically typical, non-hyperkeratotic, actinic keratosis on the face (...) and curettage are used for small areas with few lesions. Other treatment options include chemical peels, dermabrasion, laser therapy, excision and photodynamic therapy as well as retinoid therapy and intra lesional interferon. (Hadley G et al 2006) Research question In randomized controlled trials does imiquimod 5% cream provide a therapeutic advantage compared to no treatment, placebo (vehicle) or other standard therapy for the treatment of actinic keratosis on the face or balding scalp in adult patients

2009 Therapeutics Letter

16. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. (Abstract)

Treatment of vulvar intraepithelial neoplasia with topical imiquimod. Alternatives to surgery are needed for the treatment of vulvar intraepithelial neoplasia. We investigated the effectiveness of imiquimod 5% cream, a topical immune-response modulator, for the treatment of this condition.Fifty-two patients with grade 2 or 3 vulvar intraepithelial neoplasia were randomly assigned to receive either imiquimod or placebo, applied twice weekly for 16 weeks. The primary outcome was a reduction (...) ). The follow-up period was 12 months.Lesion size was reduced by more than 25% at 20 weeks in 21 of the 26 patients (81%) treated with imiquimod and in none of those treated with placebo (P<0.001). Histologic regression was significantly greater in the imiquimod group than in the placebo group (P<0.001). At baseline, 50 patients (96%) tested positive for HPV DNA. HPV cleared from the lesion in 15 patients in the imiquimod group (58%), as compared with 2 in the placebo group (8%) (P<0.001). The number

2008 NEJM Controlled trial quality: predicted high

17. Imiquimod 5% cream reduced lesion size in vulvar intraepithelial neoplasia

Imiquimod 5% cream reduced lesion size in vulvar intraepithelial neoplasia Imiquimod 5% cream reduced lesion size in vulvar intraepithelial neoplasia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Imiquimod 5% cream reduced lesion size in vulvar intraepithelial neoplasia Article Text Therapeutics Imiquimod 5% cream reduced lesion size in vulvar intraepithelial neoplasia Statistics from Altmetric.com T Helmerhorst Dr T Helmerhorst, Erasmus

2008 Evidence-Based Medicine

18. Optimal frequency of imiquimod (Aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis

Optimal frequency of imiquimod (Aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

19. Topically applied imiquimod 5% cream cleared actinic keratosis lesions Full Text available with Trip Pro

Topically applied imiquimod 5% cream cleared actinic keratosis lesions Topically applied imiquimod 5% cream cleared actinic keratosis lesions | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topically applied imiquimod 5% cream cleared actinic keratosis lesions Article Text Therapeutics Topically applied imiquimod 5% cream cleared actinic keratosis lesions Free Rodney Sinclair , MD Statistics from Altmetric.com Lebwohl M, Dinehart S

2006 Evidence-Based Medicine

20. Imiquimod 5% cream for actinic keratosis

Imiquimod 5% cream for actinic keratosis Imiquimod 5% cream for actinic keratosis Imiquimod 5% cream for actinic keratosis Perras C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Perras C. Imiquimod 5% cream for actinic keratosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004: 4 Authors' objectives (...) To summarize the available information on imiquimod 5% cream for actinic keratosis. Authors' conclusions Imiquimod 5% cream has been available since 1997 for the treatment of genital warts. Health Canada has expanded the indication to include actinic keratosis (AK). There are no trials comparing imiquimod 5% cream to standard AK therapy; placebo-controlled trials have shown an increased lesion clearance rate of 30% to 55% eight weeks post-treatment. Side effects include local skin reactions that can

2004 Health Technology Assessment (HTA) Database.